DM199 (rinvecalinase alfa)

November 24, 2026: DiaMedica Therapeutics Inc. (NASDAQ: DMAC) rescheduled its virtual KOL webinar on DM199 (rinvecalinase alfa) in fetal growth restriction (FGR) from October 23 to November 24, 2026, to include preliminary interim topline results from the second cohort of its investigator-sponsored Phase 2 early-onset FGR trial, alongside first-cohort results.

The event is expected to cover interim safety and clinical findings from the first six treated participants, with the trial principal investigator reviewing study design plus preliminary first- and second-cohort results. The Phase 2 study is an open-label, single-center, single-arm safety, pharmacodynamic, proof-of-concept trial at Tygerberg Hospital in Cape Town, South Africa.

In this trial segment, repeated subcutaneous dosing is being evaluated in up to 30 early-onset FGR subjects until delivery. Enrollment began in June 2026, and the first two cohorts totaling 12 participants have been enrolled. Dose levels are 5, 10, and up to 15 µg/kg; the third-cohort dose will be set between 1 and 15 µg/kg based on results from the first two cohorts.

This webinar is the upcoming catalyst.